ALMS trial update: envudeucitinib shows subgroup efficacy in SLE
LUMUS Phase 2b in SLE did not meet primary endpoints overall, but robust efficacy was reported in the IFNGS-high subgroup. Envudeucitinib was described as well tolerated, with Phase 3 plans underway.
In the LUMUS Phase 2b trial in SLE, the study missed its primary endpoints in the overall population, but robust efficacy was seen in the IFNGS-high subgroup, which accounts for most moderate-to-severe patients. Envudeucitinib was well tolerated, and plans are underway for Phase 3 trials focusing on the IFNGS-high subgroup. 3